基于 UPLC-Q-TOF-MS 的泽兰体内外化学成分解析及其抗卵巢癌的网络药理学机制研究OA

Objective To systematically analyze the chemical components of Lycopus lucidus and its blood-absorbed components,thereby providing a theoretical basis for elucidating the pharmacodynamic material basis of its anti-ovarian cancer effects.Methods UPLC-Q-TOF-MS was employed to characterize and identify components in the Lycopus lucidus extract,blank plasma,and drug-containing plasma,by consulting literature and databases and analyzing secondary fragment ions.The SwissTargetPrediction and GeneCards databases were used to retrieve and screen the targets of the blood-absorbed components against ovarian cancer,aiming to clarify the pharmacodynamic material basis.Finally,SKOV-3 ovarian cancer cells were treated with different concentrations of the extract to evaluate its impact on cell viability.Results By comparing the extract,blank plasma,and drug-containing plasma under identical analytical conditions,49 compounds were preliminarily identified from the Lycopus lucidus extract,including flavonoids,terpenoids,and phenolics.Among these,12 components were characterized as blood-absorbed constituents.Based on this,network pharmacology identified 10 key targets related to the anti-ovarian cancer activity of Lycopus lucidus.Furthermore,the Lycopus lucidus extract promoted SKOV-3 cell apoptosis in a dose-dependent manner.Conclusion This study systematically identified the chemical components of the Lycopus lucidus extract and its blood-absorbed constituents.The results indicate that the blood-absorbed components are likely the effective substances responsible for its anti-ovarian cancer effects,further clarifying the pharmacodynamic material basis of Lycopus lucidus against ovarian cancer.